Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.
Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD.
Mutlu L, et al. Among authors: santin ad.
Clin Exp Metastasis. 2024 Oct;41(5):765-775. doi: 10.1007/s10585-024-10297-z. Epub 2024 Jun 22.
Clin Exp Metastasis. 2024.
PMID: 38909139